Logo image of DNTH

DIANTHUS THERAPEUTICS INC (DNTH) Stock Fundamental Analysis

USA - NASDAQ:DNTH - US2528281080 - Common Stock

38.72 USD
+2.62 (+7.26%)
Last: 11/12/2025, 8:13:51 PM
38.72 USD
0 (0%)
After Hours: 11/12/2025, 8:13:51 PM
Fundamental Rating

3

Overall DNTH gets a fundamental rating of 3 out of 10. We evaluated DNTH against 531 industry peers in the Biotechnology industry. DNTH has a great financial health rating, but its profitability evaluates not so good. DNTH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DNTH had negative earnings in the past year.
In the past year DNTH has reported a negative cash flow from operations.
In the past 5 years DNTH always reported negative net income.
DNTH had a negative operating cash flow in each of the past 5 years.
DNTH Yearly Net Income VS EBIT VS OCF VS FCFDNTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of DNTH (-21.88%) is better than 74.39% of its industry peers.
The Return On Equity of DNTH (-23.12%) is better than 81.92% of its industry peers.
Industry RankSector Rank
ROA -21.88%
ROE -23.12%
ROIC N/A
ROA(3y)-33.05%
ROA(5y)-36.6%
ROE(3y)-40.68%
ROE(5y)-43.06%
ROIC(3y)N/A
ROIC(5y)N/A
DNTH Yearly ROA, ROE, ROICDNTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

DNTH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNTH Yearly Profit, Operating, Gross MarginsDNTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

DNTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DNTH has more shares outstanding
DNTH has more shares outstanding than it did 5 years ago.
DNTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DNTH Yearly Shares OutstandingDNTH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
DNTH Yearly Total Debt VS Total AssetsDNTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 29.19 indicates that DNTH is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 29.19, DNTH belongs to the top of the industry, outperforming 93.41% of the companies in the same industry.
There is no outstanding debt for DNTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 29.19
ROIC/WACCN/A
WACC8.77%
DNTH Yearly LT Debt VS Equity VS FCFDNTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 17.35 indicates that DNTH has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 17.35, DNTH belongs to the top of the industry, outperforming 93.41% of the companies in the same industry.
DNTH has a Quick Ratio of 17.35. This indicates that DNTH is financially healthy and has no problem in meeting its short term obligations.
DNTH has a better Quick ratio (17.35) than 93.41% of its industry peers.
Industry RankSector Rank
Current Ratio 17.35
Quick Ratio 17.35
DNTH Yearly Current Assets VS Current LiabilitesDNTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

2

3. Growth

3.1 Past

DNTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.20%.
Looking at the last year, DNTH shows a very negative growth in Revenue. The Revenue has decreased by -42.64% in the last year.
EPS 1Y (TTM)-39.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.08%
Revenue 1Y (TTM)-42.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-81.77%

3.2 Future

The Earnings Per Share is expected to decrease by -14.19% on average over the next years. This is quite bad
Based on estimates for the next years, DNTH will show a very strong growth in Revenue. The Revenue will grow by 97.84% on average per year.
EPS Next Y-32.21%
EPS Next 2Y-17.88%
EPS Next 3Y-15.13%
EPS Next 5Y-14.19%
Revenue Next Year-58.96%
Revenue Next 2Y-40.92%
Revenue Next 3Y-23.2%
Revenue Next 5Y97.84%

3.3 Evolution

DNTH Yearly Revenue VS EstimatesDNTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
DNTH Yearly EPS VS EstimatesDNTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DNTH. In the last year negative earnings were reported.
Also next year DNTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNTH Price Earnings VS Forward Price EarningsDNTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNTH Per share dataDNTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

DNTH's earnings are expected to decrease with -15.13% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.88%
EPS Next 3Y-15.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DNTH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DIANTHUS THERAPEUTICS INC

NASDAQ:DNTH (11/12/2025, 8:13:51 PM)

After market: 38.72 0 (0%)

38.72

+2.62 (+7.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-09 2026-03-09/amc
Inst Owners101.08%
Inst Owner Change0.89%
Ins Owners0.01%
Ins Owner Change0%
Market Cap1.54B
Revenue(TTM)3.08M
Net Income(TTM)-126.34M
Analysts88
Price Target64.72 (67.15%)
Short Float %10.05%
Short Ratio5.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.63%
Min EPS beat(2)-10.28%
Max EPS beat(2)1.02%
EPS beat(4)3
Avg EPS beat(4)0.68%
Min EPS beat(4)-10.28%
Max EPS beat(4)6.67%
EPS beat(8)5
Avg EPS beat(8)-0.09%
EPS beat(12)6
Avg EPS beat(12)-43.88%
EPS beat(16)8
Avg EPS beat(16)-32.73%
Revenue beat(2)0
Avg Revenue beat(2)-55.38%
Min Revenue beat(2)-78.11%
Max Revenue beat(2)-32.64%
Revenue beat(4)2
Avg Revenue beat(4)-13.77%
Min Revenue beat(4)-78.11%
Max Revenue beat(4)41.76%
Revenue beat(8)6
Avg Revenue beat(8)96.27%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.68%
PT rev (3m)18.48%
EPS NQ rev (1m)2.47%
EPS NQ rev (3m)5.41%
EPS NY rev (1m)0.74%
EPS NY rev (3m)-0.99%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)-35.99%
Revenue NY rev (1m)-3.53%
Revenue NY rev (3m)-39.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 500.67
P/FCF N/A
P/OCF N/A
P/B 2.82
P/tB 2.82
EV/EBITDA N/A
EPS(TTM)-3.48
EYN/A
EPS(NY)-3.61
Fwd EYN/A
FCF(TTM)-2.75
FCFYN/A
OCF(TTM)-2.75
OCFYN/A
SpS0.08
BVpS13.73
TBVpS13.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.88%
ROE -23.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.05%
ROA(5y)-36.6%
ROE(3y)-40.68%
ROE(5y)-43.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 65.43%
Cap/Sales 3.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.35
Quick Ratio 17.35
Altman-Z 29.19
F-Score2
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)96.54%
Cap/Depr(5y)74.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.08%
EPS Next Y-32.21%
EPS Next 2Y-17.88%
EPS Next 3Y-15.13%
EPS Next 5Y-14.19%
Revenue 1Y (TTM)-42.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-81.77%
Revenue Next Year-58.96%
Revenue Next 2Y-40.92%
Revenue Next 3Y-23.2%
Revenue Next 5Y97.84%
EBIT growth 1Y-69.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-162.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-162.64%
OCF growth 3YN/A
OCF growth 5YN/A

DIANTHUS THERAPEUTICS INC / DNTH FAQ

Can you provide the ChartMill fundamental rating for DIANTHUS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to DNTH.


Can you provide the valuation status for DIANTHUS THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to DIANTHUS THERAPEUTICS INC (DNTH). This can be considered as Overvalued.


How profitable is DIANTHUS THERAPEUTICS INC (DNTH) stock?

DIANTHUS THERAPEUTICS INC (DNTH) has a profitability rating of 1 / 10.


What is the earnings growth outlook for DIANTHUS THERAPEUTICS INC?

The Earnings per Share (EPS) of DIANTHUS THERAPEUTICS INC (DNTH) is expected to decline by -32.21% in the next year.